CRISPR Therapeutics AG earnings per share and revenue
On 10 de nov. de 2025, CRSP reported earnings of -1.17 USD per share (EPS) for Q3 25, beating the estimate of -1.27 USD, resulting in a 8.57% surprise. Revenue reached 889.00 mil, compared to an expected 9.08 milhão, with a -90.21% difference. The market reacted with a -0.98% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 26 analistas forecast an EPS of -1.21 USD, with revenue projected to reach 5.43 milhão USD, implying an aumentar of 3.42% EPS, and aumentar of 510.84% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were CRISPR Therapeutics AG's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, CRISPR Therapeutics AG reported EPS of -$1.17, beating estimates by 8.57%, and revenue of $889.00K, -90.21% below expectations.
How did the market react to CRISPR Therapeutics AG's Q3 2025 earnings?
The stock price moved down -0.98%, changed from $55.12 before the earnings release to $54.58 the day after.
When is CRISPR Therapeutics AG expected to report next?
The next earning report is scheduled for 09 de fev. de 2026.
What are the forecasts for CRISPR Therapeutics AG's next earnings report?
Based on 26
analistas, CRISPR Therapeutics AG is expected to report EPS of -$1.21 and revenue of $5.43M for Q4 2025.